| 2024 | Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study | TARGETED ONCOLOGY |
| 2023 | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | JAMA SURGERY |
| 2023 | Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer
| BRITISH JOURNAL OF CANCER |
| 2023 | East Asian Gynecologic Oncology Trial Group (EAGOT): founding history and future perspective
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway
| NATURE COMMUNICATIONS |
| 2023 | Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment
| CANCERS |
| 2023 | High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer
| ONCOLOGY REPORTS |
| 2023 | Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer
| FRONTIERS IN ONCOLOGY |
| 2023 | Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells
| PLOS ONE |
| 2023 | High-Dose Selenium Induces Ferroptotic Cell Death in Ovarian Cancer
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2023 | Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
| ANNALS OF LABORATORY MEDICINE |
| 2022 | THERAPEUTIC EFFECT OF SURGICAL DEBULKING OF METASTATIC LYMPH NODES IN CERVICAL CANCER STAGE IIICR: A PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL (DEBULK TRIAL) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | PROSPECTIVE MULTI-INSTITUTIONAL PHASE III TRIAL OF STANDARD OF CARE THERAPY WITH OR WITHOUT STEROTACTIC ABLATIVE RADIATION THERAPY FOR RECURRENT OVARIAN CANCER (SABR-ROC, KGOG 3064/KROG 2204) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | LATE-BREAKING ABSTRACT PRESENTATION: COMPARATIVE EFFECTIVENESS OF HIPEC FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY: MULTICENTER, PROSPECTIVE, COHORT STUDY (KGOG 3042) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | High FKBPL expression contributes to cell proliferation by regulating the cell cycle and affects prognosis in ovarian cancer patients | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | HIGH EXPRESSION OF VACUOLAR-ATPASE SUBUNIT ATP6V1B1 PROMOTES POOR PROGNOSIS AND TUMORIGENIC CHARACTERISTICS IN EPITHELIAL OVARIAN CANCER | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | HIGH EXPRESSION OF TRAFFICKING PROTEIN TRANSMEMBRANE P24 TRAFFICKING PROTEIN9 PROMOTES POOR PROGNOSIS OF EPITHELIAL OVARIAN CANCER | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | HIGH EXPRESSION OF PHOSPHODIESTERASE 1 (PDE1A) PROMOTES POOR PROGNOSIS AND ASSOCIATED WITH PLATINUM BASED CHEMOTHERAPY RESISTANCE IN EPITHELIAL OVARIAN CANCER | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
| CLINICAL CANCER RESEARCH |
| 2022 | TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis
| CANCER GENOMICS & PROTEOMICS |
| 2022 | RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer | JOURNAL OF GENE MEDICINE |
| 2022 | NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells
| JOURNAL OF CELLULAR AND MOLECULAR MEDICINE |
| 2022 | Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047) | INTERNATIONAL JOURNAL OF CANCER |
| 2022 | Overexpression of glucocorticoid receptor promotes the poor progression and induces cisplatin resistance through p38 MAP kinase in cervical cancer patients
| AMERICAN JOURNAL OF CANCER RESEARCH |
| 2022 | BRAK and APRIL as novel biomarkers for ovarian tumors | BIOMARKERS IN MEDICINE |
| 2022 | NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
| SCIENTIFIC REPORTS |
| 2022 | Identification of a novel gene signature in second-trimester amniotic fluid for the prediction of preterm birth
| SCIENTIFIC REPORTS |
| 2022 | Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models
| CANCERS |
| 2022 | Circulating Exosomal miR-1290 for Diagnosis of Epithelial Ovarian Cancer
| CURRENT ISSUES IN MOLECULAR BIOLOGY |
| 2021 | Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
| CANCER SCIENCE |
| 2021 | CRY1 Regulates Chemoresistance in Association With NANOG by Inhibiting Apoptosis via STAT3 Pathway in Patients With Cervical Cancer
| CANCER GENOMICS & PROTEOMICS |
| 2021 | LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells
| AUTOPHAGY |
| 2021 | Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
| EXPERIMENTAL AND THERAPEUTIC MEDICINE |
| 2021 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2021 | Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2021 | The Combination of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) is an Effective Prognostic Biomarker in Cervical Cancer | INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY |
| 2021 | SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
| CANCERS |
| 2021 | Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma
| MOLECULAR ONCOLOGY |
| 2021 | MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors
| PLOS PATHOGENS |
| 2020 | Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
| CANCERS |
| 2020 | Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study | CLINICAL THERAPEUTICS |
| 2020 | TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels
| CANCERS |
| 2020 | Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer
| CANCER GENOMICS & PROTEOMICS |
| 2020 | CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer | GYNECOLOGIC ONCOLOGY |
| 2020 | HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors
| NATURE COMMUNICATIONS |
| 2019 | Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer
| BMC CANCER |
| 2019 | Clear Cell Carcinoma Arising from Endometriosis at the Cesarean Scar Site: A Case Report
| Archives of Clinical and Medical Case Reports |
| 2019 | Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer | Cancer genomics & Proteomics |
| 2019 | ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer
| CANCERS |
| 2019 | Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth | INTERNATIONAL JOURNAL OF HYPERTHERMIA |
http://orcid.org/0000-0001-6599-7065
(34771509800)
